Advances in prodrug design

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2014-05-27T11:21:38Z
dc.date.available2014-05-27T11:21:38Z
dc.date.created2014-05-27T11:21:38Z
dc.date.issued2005-10-01
dc.identifierMini-Reviews in Medicinal Chemistry, v. 5, n. 10, p. 893-914, 2005.
dc.identifier1389-5575
dc.identifierhttp://hdl.handle.net/11449/68433
dc.identifier10.2174/138955705774329528
dc.identifierWOS:000231837000003
dc.identifier2-s2.0-24944549193
dc.identifier9734333607975413
dc.identifier0000-0003-4141-0455
dc.description.abstractThe background of prodrug design is presented herein as the basis for introducing new and advanced latent systems, taking into account mainly the versatility of polymers and other macromolecules as carriers. PDEPT (Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy); GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy); ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-directed enzyme-activated prodrug therapy) are briefly described and some examples are given. © 2005 Bentham Science Publishers Ltd.
dc.languageeng
dc.relationMini-Reviews in Medicinal Chemistry
dc.relation2.645
dc.relation0,567
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectLatent advanced systems
dc.subjectMacromolecules carriers
dc.subjectProdrug design
dc.subjectSelective delivery systems
dc.subjectaminosalicylic acid
dc.subjectampicillin
dc.subjectantiinflammatory agent
dc.subjectantileishmanial agent
dc.subjectantimalarial agent
dc.subjectantineoplastic agent
dc.subjectbisphosphonic acid derivative
dc.subjectcytochrome P450
dc.subjectdiclofenac
dc.subjectdoxorubicin
dc.subjectflucytosine
dc.subjectibuprofen
dc.subjectirinotecan
dc.subjectisoniazid
dc.subjectketoprofen
dc.subjectmevinolin
dc.subjectmitomycin
dc.subjectnitrofural
dc.subjectpaclitaxel derivative
dc.subjectphotosensitizing agent
dc.subjectprodrug
dc.subjectsalazosulfapyridine
dc.subjecttacrolimus
dc.subjecttestosterone derivative
dc.subjecttiaprofenic acid
dc.subjecttolmetin
dc.subjecttrigonelline
dc.subjecttryptamine derivative
dc.subjectunindexed drug
dc.subjectantibody directed enzyme prodrug therapy
dc.subjectbactericidal activity
dc.subjectbinding affinity
dc.subjectblood brain barrier
dc.subjectChagas disease
dc.subjectdiarrhea
dc.subjectdrug absorption
dc.subjectdrug activation
dc.subjectdrug design
dc.subjectdrug distribution
dc.subjectdrug identification
dc.subjectdrug receptor binding
dc.subjectdrug screening
dc.subjectdrug selectivity
dc.subjectdrug stability
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectdrug targeting
dc.subjectdrug transformation
dc.subjectgastrointestinal toxicity
dc.subjectgene expression
dc.subjecthuman
dc.subjecthypercholesterolemia
dc.subjectin vivo study
dc.subjectmacromolecule
dc.subjectmalaria
dc.subjectminimum inhibitory concentration
dc.subjectnephrotoxicity
dc.subjectorganoleptic property
dc.subjectosteoporosis
dc.subjectreview
dc.subjectrheumatoid arthritis
dc.subjectstructure activity relation
dc.subjectstructure analysis
dc.subjecttuberculosis
dc.subjectulcerative colitis
dc.subjectAnimals
dc.subjectAntibodies
dc.subjectDrug Carriers
dc.subjectDrug Delivery Systems
dc.subjectDrug Design
dc.subjectGene Therapy
dc.subjectHumans
dc.subjectLectins
dc.subjectMacromolecular Substances
dc.subjectOsteoporosis
dc.subjectProdrugs
dc.subjectViruses
dc.titleAdvances in prodrug design
dc.typeOtros


Este ítem pertenece a la siguiente institución